Investigating how UBR5 contributes to cancer growth and immune response
Official title: UBR5's mechanisms of action in tumorigenesis and immunoregulation
Funded at Weill Medical Coll of Cornell Univ · NIH-11032883 · Data updated 2026-11-12
This study is looking at how a gene called UBR5 affects the growth and spread of aggressive breast and ovarian cancers, and how it might help these tumors avoid the immune system, with the goal of finding new treatment options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | March 1, 2023 |
| Project end | February 29, 2028 |
| Funding year | 2025 |
| Award (this year) | $655,228 |
| NIH project number | 5R01CA273716-03 |
| Project ID | NIH-11032883 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients diagnosed with aggressive breast or ovarian cancers, particularly those with genetic alterations in the UBR5 gene.
✕Less likely to help
Patients with early-stage or less aggressive forms of breast or ovarian cancer may not receive direct benefits from this research.
What this research studies
This research focuses on understanding the role of the UBR5 gene in various aggressive cancers, particularly breast and ovarian cancer. It examines how UBR5 amplifications and overexpression affect tumor growth and metastasis, as well as the immune system's response to these tumors. By conducting both laboratory experiments and clinical analyses, the research aims to uncover the mechanisms by which UBR5 influences cancer progression and immune evasion, potentially leading to new therapeutic strategies for patients with these cancers.
Why it matters
Potential benefit: If successful, this research could lead to the development of novel therapies that improve survival rates for patients with aggressive breast and ovarian cancers.
How similar studies have gone: Previous research has shown promising results in targeting similar oncogenes and their pathways, indicating potential for success in this area.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Ma, Xiaojing — Weill Medical Coll of Cornell Univ
- Study coordinator: Ma, Xiaojing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.